no cortisol/prolactin changes at GH-effective concentrations Jimenez-Reina et al
MASH resolution: The trial measured this at 52 weeks
However, it is important to note that in our study, all patients who were taking valproic acid and carbamazepine were on polytherapy
Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory
[1] [2] As of 20242025, retatrutide remains under clinical investigation and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for routine clinical use
In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings
